Respiratory Syncytial Virus

Hospitalization costs from respiratory syncytial virus infection are driven by older age and comorbidities.

The 2022-2023 COVID-19 season did not have a significant surge of COVID-19 like it did early on in the COVID-19 pandemic.

Vaccination is especially important for older adults with any chronic health conditions because vaccines can prevent serious illness and resulting complications down the road.

Arexvy is the first respiratory syncytial virus (RSV) vaccine approved in the United States for the prevention of lower respiratory tract disease caused by RSV in individuals 60 years of age and older.

Results of a review show that lessons learned from the pandemic apply to the respiratory syncytial virus.

Atypical respiratory syncytial virus epidemics may continue, and testing patients for multiple respiratory pathogens when indicated might be necessary.

Respiratory syncytial virus (RSV) vaccine demonstrated efficacy of 66.7% in reducing RSV-associated lower respiratory tract illness with at least 2 signs or symptoms in older adults.

State-level respiratory syncytial virus hospitalization rates for 2022 could be the highest seen since 2006, analysis published in Frontiers in Pediatrics indicate.

The trial did not meet the second primary efficacy endpoint of medically attended respiratory syncytial virus-associated lower respiratory tract illness.

Not only are pharmacists easily accessible to the public, they are also highly visible as a source for travel immunization services.

The company announced the initiation of the EVERGREEN study, which was aimed to evaluate the efficacy, safety, and immunogenicity of the investigational respiratory syncytial virus vaccine, in 2021.

Prior to the pandemic, the seasonality of respiratory syncytial virus followed a pattern; now, this pattern of disease spread has changed significantly.

The test did not reach the World Health Organization’s minimum performance requirement, which is 80% sensitivity for SARS-CoV-2, in the study population.

Findings from the ongoing Adult Respiratory Syncytial Virus phase 3 trial suggest RSVPreF3 OA vaccine is effective and safe for individuals aged 60 years and older.

Interventions targeting respiratory viruses should be considered as a means of protecting against invasive pneumococcal disease in children, study finds.

The FDA set a Prescription Drug User Fee Act for May 2023 for Pfizer’s respiratory syncytial virus bivalent vaccine candidate.

Phase 3 trial results indicate efficacy against respiratory syncytial virus-lower respiratory tract disease in individuals aged 60 years and older.

The COVID-19 and flu test is a single-use at-home test kit that uses self-collected nasal swab samples and provides results in approximately 30 minutes.

If approved, the vaccine would be the first immunization for use in pregnant individuals to help protect against the complications of respiratory syncytial virus in infants from birth through 6 months.

One of the major concerns about getting a flu vaccine is its safety for women during pregnancy.

Despite the large number of prescription products available, nondrug therapies often work just as well.

Pharmacists play a vital role in educating patients about differentiating among the common cold, COVID-19, influenza, and respiratory syncytial virus.

Single nasal swab test can determine whether a patient has COVID-19, influenza, respiratory syncytial virus, or a combination of these viruses in as little as 2 hours.

The mRNA-1345 vaccine candidate was previously granted Fast Track designation by the FDA in August 2021.

Respiratory syntactical virus burdens quality of life and can lead to long-term health outcomes.